Belite Bio to Participate in Four Upcoming Investor Conferences
Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company specializing in degenerative retinal disease therapeutics, has announced its participation in four upcoming investor conferences in May 2025:
- Deutsche Bank Depositary Receipts Virtual Conference on May 15 at 12:30 PM ET
- H.C. Wainwright BioConnect Investor Conference at NASDAQ on May 20 at 5:00 PM ET
- Stifel Ophthalmology Forum on May 27 at 11:00 AM ET
- Benchmark's Healthcare House Call Conference on May 29 at 12:45 PM ET
Webcasts of all presentations will be available on Belite Bio's investor relations website and archived for 90 days.
Belite Bio (NASDAQ: BLTE), una societ脿 biofarmaceutica in fase clinica specializzata in terapie per malattie degenerative della retina, ha annunciato la sua partecipazione a quattro prossimi convegni per investitori previsti a maggio 2025:
- Conferenza virtuale Deutsche Bank Depositary Receipts il 15 maggio alle 12:30 ET
- Conferenza per investitori H.C. Wainwright BioConnect al NASDAQ il 20 maggio alle 17:00 ET
- Stifel Ophthalmology Forum il 27 maggio alle 11:00 ET
- Benchmark's Healthcare House Call Conference il 29 maggio alle 12:45 ET
I webcast di tutte le presentazioni saranno disponibili sul sito web delle relazioni con gli investitori di Belite Bio e archiviati per 90 giorni.
Belite Bio (NASDAQ: BLTE), una compa帽铆a biofarmac茅utica en etapa cl铆nica especializada en terapias para enfermedades degenerativas de la retina, ha anunciado su participaci贸n en cuatro pr贸ximas conferencias para inversores en mayo de 2025:
- Conferencia virtual Deutsche Bank Depositary Receipts el 15 de mayo a las 12:30 PM ET
- Conferencia para inversores H.C. Wainwright BioConnect en NASDAQ el 20 de mayo a las 5:00 PM ET
- Foro de Oftalmolog铆a Stifel el 27 de mayo a las 11:00 AM ET
- Conferencia Healthcare House Call de Benchmark el 29 de mayo a las 12:45 PM ET
Las retransmisiones en l铆nea de todas las presentaciones estar谩n disponibles en el sitio web de relaciones con inversores de Belite Bio y archivadas durante 90 d铆as.
Belite Bio (NASDAQ: BLTE)電� 韲错枆靹� 毵濍 歆堩櫂 旃橂鞝滊ゼ 鞝勲鞙茧 頃橂姅 鞛勳儊 雼硠 氚旍澊鞓れ牅鞎� 須岇偓搿�, 2025雲� 5鞗旍棎 鞓堨爼霅� 雱� 瓯挫潣 韴瀽鞛� 旎嵓霟办姢鞐� 彀胳棳頃� 鞓堨爼鞛勳潉 氚滍憸頄堨姷雼堧嫟:
- 5鞗� 15鞚� 鞓ろ泟 12鞁� 30攵�(霃欕秬鞁滉皠)鞐� 鞐措Μ電� Deutsche Bank Depositary Receipts 臧�靸� 旎嵓霟办姢
- 5鞗� 20鞚� 鞓ろ泟 5鞁�(霃欕秬鞁滉皠)鞐� NASDAQ鞐愳劀 臧滌禍霅橂姅 H.C. Wainwright BioConnect 韴瀽鞛� 旎嵓霟办姢
- 5鞗� 27鞚� 鞓れ爠 11鞁�(霃欕秬鞁滉皠)鞐� 鞐措Μ電� Stifel 鞎堦臣 韽熂
- 5鞗� 29鞚� 鞓ろ泟 12鞁� 45攵�(霃欕秬鞁滉皠)鞐� 鞐措Μ電� Benchmark鞚� Healthcare House Call 旎嵓霟办姢
氇摖 氚滍憸鞚� 鞗轨簮鞀ろ姼電� Belite Bio 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼鞐愳劀 鞁滌箔頃� 靾� 鞛堨溂氅� 90鞚� 霃欖晥 鞎勳勾鞚措笇霅╇媹雼�.
Belite Bio (NASDAQ : BLTE), une soci茅t茅 biopharmaceutique en phase clinique sp茅cialis茅e dans les th茅rapies des maladies d茅g茅n茅ratives de la r茅tine, a annonc茅 sa participation 脿 quatre prochaines conf茅rences pour investisseurs en mai 2025 :
- Conf茅rence virtuelle Deutsche Bank Depositary Receipts le 15 mai 脿 12h30 ET
- Conf茅rence investisseurs H.C. Wainwright BioConnect au NASDAQ le 20 mai 脿 17h00 ET
- Forum d'ophtalmologie Stifel le 27 mai 脿 11h00 ET
- Conf茅rence Healthcare House Call de Benchmark le 29 mai 脿 12h45 ET
Les webcasts de toutes les pr茅sentations seront disponibles sur le site des relations investisseurs de Belite Bio et archiv茅s pendant 90 jours.
Belite Bio (NASDAQ: BLTE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Therapeutika f眉r degenerative Netzhauterkrankungen spezialisiert hat, hat seine Teilnahme an vier bevorstehenden Investorenkonferenzen im Mai 2025 angek眉ndigt:
- Deutsche Bank Depositary Receipts Virtuelle Konferenz am 15. Mai um 12:30 Uhr ET
- H.C. Wainwright BioConnect Investorenkonferenz an der NASDAQ am 20. Mai um 17:00 Uhr ET
- Stifel Ophthalmology Forum am 27. Mai um 11:00 Uhr ET
- Benchmark's Healthcare House Call Konferenz am 29. Mai um 12:45 Uhr ET
Webcasts aller Pr盲sentationen werden auf der Investor-Relations-Website von Belite Bio verf眉gbar sein und f眉r 90 Tage archiviert.
- None.
- None.
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in four upcoming investor conferences. Details of the presentations are as follows:
- Deutsche Bank Depositary Receipts Virtual Investor Conference (Virtual)
- May 15, 2025, at 12:30 pm ET, corporate presentation
- H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ (New York, NY)
- May 20, 2025, at 5:00 pm ET, fireside chat
- Stifel 2025 Ophthalmology Forum (Virtual)
- May 27, 2025, at 11:00 am ET, fireside chat
- Benchmark's Healthcare House Call One-on-One Conference (Virtual)
- May 29, 2025, at 12:45 pm ET, fireside chat
Webcast Link Instructions
A webcast of each presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: . The replays will be archived for 90 days following the presentation date.
About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite鈥檚 lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on聽,听,听,听聽or visit us at聽.
Media and Investor Relations Contact:
Jennifer Wu
Julie Fallon
FAQ
What investor conferences is BLTE participating in during May 2025?
How can investors access Belite Bio's conference presentations?
What is Belite Bio's main business focus?
Which of BLTE's May 2025 conferences will be virtual vs in-person?
